Vivos Therapeutics approves new equity plan and amended CEO/CFO employment deals

Vivos Therapeutics, Inc.

Board approved 2024 Omnibus Plan (subject to stockholder vote) with 1,600,000 shares available for future awards.
Contingent option grants: CEO Huntsman 315,421 ISOs, CFO Amman 149,533 ISOs at $2.62/share, 3-year vesting.
Amended employment agreements effective Jan 1, 2025 raise CEO base salary to $450,000 and CFO to $320,000.
Severance: 12-month salary continuation on non-cause termination; 24 months after change-in-control; full equity vesting.
New plan will replace 2019 Plan; unused shares retired if stockholders approve at 2024 Annual Meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.